Arch Therapeutics (ARTH) S-1/A 25 Aug 22 2022 Q3 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0001537561
Entity Registrant Name	Arch Therapeutics, Inc.
Amendment Flag	true
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	S-1/A
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	46-0524102
Entity Address, Address Line One	235 Walnut St., Suite 6
Entity Address, City or Town	Framingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01702
City Area Code	617
Local Phone Number	431-2313
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Amendment Description	This Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 19, 2022 (File No. 333-267004) (this "Amendment No. 1") is being filed solely (i) to file the Inline XBRL data to the Financial Statements and Notes thereto and (ii) to update the Consolidated Statements of Cash Flows (Unaudited) in the Financial Statements to remove the six-month period ended March 31, 2022 and 2021 and to include the nine-month period ended June 30, 2022 and 2021. Accordingly, this Amendment No. 1 consists solely of the facing page, Part II, Item 16, and the signature page. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement. Accordingly, a preliminary prospectus has been omitted.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Current assets:
Cash	$ 2,266,639	$ 959,309
Inventory	1,093,765	967,993
Prepaid expense and other current assets	307,341	215,673
Total current assets	3,667,745	2,142,975
Long-term assets:
Property and equipment, net	5,240	4,552
Other assets	3,500	3,500
Total long-term assets	8,740	8,052
Total assets	3,676,485	2,151,027
Long-term liabilities:
Accounts payable	408,083	342,050
Accrued expenses and other liabilities	319,464	248,968
Current portion of derivative liability	1,000,000	0
Current portion of PPP Loan	0	37,442
Total current liabilities	1,727,547	628,460
Long-term portion of PPP loan	0	138,858
Accrued interest	167,137	17,781
Derivative liability, net of current portion	1,207,475	2,316,419
Total long-term liabilities	2,974,612	3,023,058
Total liabilities	4,702,159	3,651,518
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.001 par value, 800,000,000 shares authorized; 237,169,770 shares issued as of June 30, 2022 and September 30, 2021, respectively, and 236,994,770 and 236,719,770 shares outstanding as of June 30, 2022 and September 30, 2021, respectively	236,720	193,045
Additional paid-in capital	48,534,525	41,862,901
Accumulated deficit	(49,796,919)	(43,556,437)
Total stockholders’ deficit	(1,025,674)	(1,500,491)
Total liabilities and stockholders’ deficit	3,676,485	2,151,027
Convertible Notes Payable Series One [Member]
Long-term liabilities:
Convertible notes	550,000	550,000
Convertible Notes Payable Series Two [Member]
Long-term liabilities:
Convertible notes	$ 1,050,000	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares Authorized (in shares)	800,000,000	800,000,000	800,000,000
Common Stock, Shares Issued (in shares)	237,169,770	237,169,770	193,044,766
Common Stock, Shares Outstanding (in shares)	236,994,770	236,719,770	193,044,766

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Revenue	$ 11,565	$ 0
Operating expenses:
Cost of revenues	26,282	0
Selling, general and administrative expense	5,009,323	3,741,020
Research and development expense	1,353,084	1,611,094
Total costs and expenses	6,388,689	5,352,114
Loss from operations	(6,377,124)	(5,352,114)
Other income:
Interest expense	(150,531)	(18,534)
Other Nonoperating Income (Loss) Debt Forgiveness Amount	178,229	0
Decrease to fair value of derivative	108,944	679,271
Total other income	136,642	660,737
Net loss	$ (6,240,482)	$ (4,691,377)
Loss per share - basic and diluted
Net loss per common share - basic and diluted (in dollars per share)	$ (0.03)	$ (0.02)
Weighted common shares - basic and diluted (in shares)	220,001,412	188,051,683

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Sep. 30, 2019	172,612,233
Balance at Sep. 30, 2019	$ 172,612	$ 37,885,151	$ (38,865,060)	$ (807,297)
Net loss	$ 0	0	(4,691,377)	(4,691,377)
Shares issued for the exercise of warrants (in shares)	5,181,819
Shares issued for the exercise of warrants	$ 5,182	927,546	0	932,728
Issuance of common stock and warrants, net of financing costs (in shares)	14,285,714
Issuance of common stock and warrants, net of financing costs	$ 14,286	2,152,876	0	2,167,162
Vesting of restricted stock (in shares)	965,000
Vesting of restricted stock	$ 965	(965)	0	0
Stock-based compensation expense	$ 0	898,293	0	$ 898,293
Balance (in shares) at Sep. 30, 2020	193,044,766			193,044,766
Balance at Sep. 30, 2020	$ 193,045	41,862,901	(43,556,437)	$ (1,500,491)
Shares issued for the exercise of warrants (in shares)				0
Vesting of restricted stock		(550)	0	$ 0
Stock-based compensation expense		372,196	0	372,196
Balance at Jun. 30, 2021		48,410,655	(48,031,742)	$ 615,633
Balance (in shares) at Sep. 30, 2020	193,044,766			193,044,766
Balance at Sep. 30, 2020	$ 193,045	41,862,901	(43,556,437)	$ (1,500,491)
Net loss	$ 0	0	(6,240,482)	(6,240,482)
Issuance of common stock and warrants, net of financing costs (in shares)	43,125,004
Issuance of common stock and warrants, net of financing costs	$ 43,125	6,176,108	0	6,219,233
Stock-based compensation expense	$ 0	496,066	0	496,066
Vesting of restricted stock issued (in shares)	550,000
Vesting of restricted stock issued	$ 550	(550)		$ 0
Balance (in shares) at Sep. 30, 2021	236,719,770			236,719,770
Balance at Sep. 30, 2021	$ 236,720	48,534,525	(49,796,919)	$ (1,025,674)
Balance at Mar. 31, 2021		48,316,799	(46,501,837)	2,051,682
Stock-based compensation expense		93,856	0	93,856
Balance at Jun. 30, 2021		48,410,655	(48,031,742)	615,633
Balance at Sep. 30, 2021	$ 236,720	48,534,525	(49,796,919)	$ (1,025,674)
Shares issued for the exercise of warrants (in shares)				0
Vesting of restricted stock		(275)	0	$ 0
Stock-based compensation expense		397,470	0	$ 397,470
Balance (in shares) at Jun. 30, 2022				236,994,770
Balance at Jun. 30, 2022		48,931,720	(53,184,214)	$ (4,015,499)
Balance at Mar. 31, 2022		48,841,040	(52,137,384)	(3,059,424)
Vesting of restricted stock		(75)	0	0
Stock-based compensation expense		90,755	0	$ 90,755
Balance (in shares) at Jun. 30, 2022				236,994,770
Balance at Jun. 30, 2022		$ 48,931,720	$ (53,184,214)	$ (4,015,499)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (3,387,295)	$ (4,475,305)	$ (6,240,482)	$ (4,691,377)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	2,397	1,788	2,587	6,926
Stock-based compensation	397,470	372,196	496,066	898,293
(Decrease) to fair value of derivative			(108,944)	(679,271)
Inventory obsolescence charge	248,073	181,988	181,988	60,385
Gain on forgiveness of loan	0	(178,229)	(178,229)	0
(Increase) decrease in:
Inventory	(582,572)	(42,215)	(307,760)	(681,731)
Prepaid expenses and other current assets	223,854	(163,135)	(91,668)	147,032
Increase (decrease) in:
Accounts payable	1,288,130	(64,853)	66,033	(191,505)
Accrued interest	119,671	110,956	151,285	0
Accrued expenses and other liabilities	(96,370)	(80,324)	70,496	86,493
Net cash used in operating activities	(2,786,642)	(4,446,077)	(5,958,628)	(5,044,755)
Cash flows from investing activities:
Purchases of property and equipment	0	(3,275)	(3,275)	(2,455)
Net cash used in investing activities	0	(3,275)	(3,275)	(2,455)
Cash flows from financing activities:
Proceeds received from series 2 convertible notes	0	1,050,000	1,050,000	550,000
Proceeds received from PPP loan			0	176,300
Proceeds from issued common stock and warrants, net of financing costs	0	6,219,233	6,219,233	2,167,162
Proceeds from exercise of warrants			0	932,728
Net cash provided by financing activities	575,000	7,269,233	7,269,233	3,826,190
Net increase (decrease) in cash			1,307,330	(1,221,020)
Cash, beginning of year	2,266,639	959,309	959,309	2,180,329
Cash, end of period			2,266,639	959,309
Non-cash financing activities:
Issuance of restricted stock			0	965
Issuance of restricted stock for services	$ 29,831	$ 103,750	103,750	93,500
Series J Warrants cost			$ 0	$ 219,737

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Cash	$ 54,997	$ 2,266,639
Inventory	1,428,264	1,093,765
Prepaid expense and other current assets	83,487	307,341
Total current assets	1,566,748	3,667,745
Long-term assets:
Property and equipment, net	2,843	5,240
Other assets	3,500	3,500
Total long-term assets	6,343	8,740
Total assets	1,573,091	3,676,485
Current liabilities:
Accounts payable	1,696,213	408,083
Accrued expense and other liabilities	223,094	319,464
Current portion of derivative liability	0	1,000,000
Total current liabilities	1,919,307	1,727,547
Long-term liabilities:
Advances from investors	575,000	0
Accrued interest	286,808	167,137
Derivative liability, net of current portion	1,207,475	1,207,475
Total long-term liabilities	3,669,283	2,974,612
Total liabilities	5,588,590	4,702,159
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.001 par value, 800,000,000 shares authorized; 237,169,770 shares issued as of June 30, 2022 and September 30, 2021, respectively, and 236,994,770 and 236,719,770 shares outstanding as of June 30, 2022 and September 30, 2021, respectively	236,995	236,720
Additional paid-in capital	48,931,720	48,534,525
Accumulated deficit	(53,184,214)	(49,796,919)
Total stockholders’ deficit	(4,015,499)	(1,025,674)
Total liabilities and stockholders’ deficit	1,573,091	3,676,485
Series 1 Convertible Notes [Member]
Long-term liabilities:
Convertible notes	550,000	550,000
Series 2 Convertible Notes [Member]
Long-term liabilities:
Convertible notes	$ 1,050,000	$ 1,050,000

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares Authorized (in shares)	800,000,000	800,000,000	800,000,000
Common Stock, Shares Issued (in shares)	237,169,770	237,169,770	193,044,766
Common Stock, Shares Outstanding (in shares)	236,994,770	236,719,770	193,044,766

Consolidated Statements of Op_2

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue	$ 6,261	$ 0	$ 14,086	$ 10,000
Operating expense:
Cost of revenues	17,140	0	51,363	10,102
Selling, general and administrative expense	836,215	1,370,395	3,308,227	3,600,419
Research and development expense	159,846	297,553	922,120	1,051,755
Total costs and expenses	1,013,200	1,667,948	4,281,710	4,662,276
Loss from operations	(1,006,940)	(1,667,948)	(4,267,624)	(4,652,276)
Other income (expense):
Interest expense	(39,890)	(40,186)	(119,671)	(110,202)
Gain on forgiveness of loan	0	178,229		178,229
Decrease to fair value of derivative liability	0	0	1,000,000	108,944
Total other income (expense)	(39,890)	138,043	880,329	176,971
Net loss	$ (1,046,830)	$ (1,529,905)	$ (3,387,295)	$ (4,475,305)
Loss per share - basic and diluted
Net loss per common share - basic and diluted (in dollars per share)	$ 0	$ (0.01)	$ (0.01)	$ (0.02)
Weighted common shares - basic and diluted (in shares)	236,947,517	236,719,770	236,853,195	214,289,567

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Common Stock Outstanding [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Sep. 30, 2019		$ 37,885,151	$ (38,865,060)	$ (807,297)
Net loss				(4,691,377)
Vesting of restricted stock		(965)	0	0
Stock-based compensation expense		898,293	0	898,293
Vesting of restricted stock		(965)	0	0
Balance (in shares) at Sep. 30, 2020	193,044,766
Balance at Sep. 30, 2020	$ 193,045	41,862,901	(43,556,437)	(1,500,491)
Net loss	$ 0	0	(4,475,305)	(4,475,305)
Vesting of restricted stock (in shares)	550,000
Vesting of restricted stock	$ 550	(550)	0	0
Stock-based compensation expense	$ 0	372,196	0	372,196
Issuance of common stock and warrants, net of financing costs (in shares)	43,125,004
Issuance of common stock and warrants, net of financing costs	$ 43,125	6,176,108	0	6,219,233
Vesting of restricted stock (in shares)	550,000
Vesting of restricted stock	$ 550	(550)	0	0
Balance (in shares) at Jun. 30, 2021	236,719,770
Balance at Jun. 30, 2021	$ 236,720	48,410,655	(48,031,742)	615,633
Balance (in shares) at Sep. 30, 2020	193,044,766
Balance at Sep. 30, 2020	$ 193,045	41,862,901	(43,556,437)	(1,500,491)
Net loss				(6,240,482)
Stock-based compensation expense		496,066	0	496,066
Balance (in shares) at Sep. 30, 2021	236,719,770
Balance at Sep. 30, 2021	$ 236,720	48,534,525	(49,796,919)	(1,025,674)
Balance (in shares) at Mar. 31, 2021	236,719,770
Balance at Mar. 31, 2021	$ 236,720	48,316,799	(46,501,837)	2,051,682
Net loss	0	0	(1,529,905)	(1,529,905)
Stock-based compensation expense	$ 0	93,856	0	93,856
Balance (in shares) at Jun. 30, 2021	236,719,770
Balance at Jun. 30, 2021	$ 236,720	48,410,655	(48,031,742)	615,633
Balance (in shares) at Sep. 30, 2021	236,719,770
Balance at Sep. 30, 2021	$ 236,720	48,534,525	(49,796,919)	(1,025,674)
Net loss	$ 0	0	(3,387,295)	(3,387,295)
Vesting of restricted stock (in shares)	275,000
Vesting of restricted stock	$ 275	(275)	0	0
Stock-based compensation expense	$ 0	397,470	0	397,470
Vesting of restricted stock (in shares)	275,000
Vesting of restricted stock	$ 275	(275)	0	0
Balance (in shares) at Jun. 30, 2022	236,994,770
Balance at Jun. 30, 2022	$ 236,995	48,931,720	(53,184,214)	(4,015,499)
Balance (in shares) at Mar. 31, 2022	236,919,770
Balance at Mar. 31, 2022	$ 236,920	48,841,040	(52,137,384)	(3,059,424)
Net loss	$ 0	0	(1,046,830)	(1,046,830)
Vesting of restricted stock (in shares)	75,000
Vesting of restricted stock	$ 75	(75)	0	0
Stock-based compensation expense	$ 0	90,755	0	90,755
Vesting of restricted stock (in shares)	75,000
Vesting of restricted stock	$ 75	(75)	0	0
Balance (in shares) at Jun. 30, 2022	236,994,770
Balance at Jun. 30, 2022	$ 236,995	$ 48,931,720	$ (53,184,214)	$ (4,015,499)

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (1,046,830)	$ (1,529,905)	$ (3,387,295)	$ (4,475,305)	$ (6,240,482)	$ (4,691,377)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	799	799	2,397	1,788	2,587	6,926
Stock-based compensation			397,470	372,196	496,066	898,293
Decrease to fair value of derivative liability	0	0	(1,000,000)	(108,944)
Inventory obsolescence charge			248,073	181,988	181,988	60,385
Gain on forgiveness of loan			0	(178,229)	(178,229)	0
Changes in operating assets and liabilities:
Inventory			(582,572)	(42,215)	(307,760)	(681,731)
Prepaid expenses and other current assets			223,854	(163,135)	(91,668)	147,032
Accounts payable			1,288,130	(64,853)	66,033	(191,505)
Accrued interest			119,671	110,956	151,285	0
Accrued expenses and other liabilities			(96,370)	(80,324)	70,496	86,493
Net cash used in operating activities			(2,786,642)	(4,446,077)	(5,958,628)	(5,044,755)
Cash flows from investing activities:
Purchases of property and equipment			0	(3,275)	(3,275)	(2,455)
Net cash used in investing activities			0	(3,275)	(3,275)	(2,455)
Cash flows from financing activities:
Proceeds received from advances from investors			575,000	0
Proceeds received from series 2 convertible notes			0	1,050,000	1,050,000	550,000
Proceeds from issuance common stock and warrants, net of financing costs			0	6,219,233	6,219,233	2,167,162
Net cash provided by financing activities			575,000	7,269,233	7,269,233	3,826,190
Net increase (decrease) in cash			(2,211,642)	2,819,881
Cash, beginning of period			2,266,639	959,309	959,309
Cash, end of period	$ 54,977	$ 3,779,190	54,977	3,779,190	2,266,639	959,309
Non-cash financing activities:
Issuance of restricted stock for services			$ 29,831	$ 103,750	$ 103,750	$ 93,500

Note 1 - Description of Busines

Note 1 - Description of Business	12 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Arch Therapeutics, Inc., (together with its subsidiary, the “Company” or “Arch”) was incorporated under the laws of the State of Nevada on September 16, 2009, June 26, 2013, ABS was incorporated under the laws of the Commonwealth of Massachusetts on March 6, 2006 April 7, 2008, The Company only recently commenced commercial sales of our first AC5® The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its potential products. However, there can be no not

Note 2 - Summary Of Significant

Note 2 - Summary Of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“ US GAAP Although the Company believes that the disclosures in these unaudited interim consolidated financial statements are adequate to make the information presented not SEC 10 September 30, 2021, December 17, 2021 ( Annual Report For a complete summary of the Company’s significant accounting policies, please refer to Note 2 8 no nine June 30, 2022. Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three June 30, 2022 September 30, 2021. Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not FASB ASC 360, Property, Plant and Equipment three nine June 30, 2022 2021 not Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s lease does not Income Taxes In accordance with FASB ASC Topic 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not Revenue In accordance with FASB ASC Topic 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third Cost of Revenue Cost of revenue includes product costs, warehousing, overhead allocation and royalty expense. Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation ASC 718 718, Black-Scholes Model The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the Common Stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99, no Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At June 30, 2022 September 30, 2021, 10 Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging ASC 815 no Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product(s) and eventually attaining and maintaining profitable operations. As of the date of issuance of the accompanying consolidated financial statements , the Company will be required to raise additional capital, obtain alternative means of financial support, or both, in order to continue to fund operations, and therefore there is substantial doubt about the Company’s ability to continue as a going concern. The Company expects to incur substantial expenses into the foreseeable future for the research, development and commercialization of its current and potential other products. In addition, the Company will require additional financing in order to seek to license or acquire new assets, research and develop any potential patents and the related compounds, and obtain any further intellectual property that the Company may APIs AC5® June 28, 2018 (“ 2018 2018 not 2018 20% 6 2018 The continued spread of coronavirus and geopolitical conflicts, including the recent war in Ukraine, as well as uncertain market conditions, may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not	2. The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“ US GAAP Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Recently Issued and Adopted Accounting Guidance Accounting Standards Update (ASU) 2018 13, 820 August 2018. 820. December 15, 2019. 2018 13 first 2021, ASU 2020 06, 470 02 815 40 August 2020. December 15, 2023. not Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three September 30, 2021 2020. Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not 360, Property, Plant and Equipment September 30, 2021 2020 not Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use (“ROU“) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our lease does not September 30, 2021 2020, September 30, 2021 2020, Income Taxes In accordance with FASB ASC 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not Revenue In accordance with FASB ASC 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third Cost of Revenues Cost of revenues includes product costs, warehousing, overhead allocation and royalty expenses. Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation 718” 718, The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99 no Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At September 30, 2021 2020, Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging no Financial Statement Reclassification Certain balances in the prior year consolidated financial statements have been reclassified for comparison purposes to conform to the presentation in the current period consolidated financial statements. Subsequent Events The Company evaluated all events or transactions through December 16, 2021, no 15 Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product and eventually attaining and maintaining profitable operations. In particular, as of September 30, 2021, may AC5® February 20, 2017 ( “2017 June 28, 2018 ( “2018 2017 2018 not three 2017 2018 20% 2017 2018 2021 2021 February 11, 2022; may may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not

Note 3 - Property and Equipment

Note 3 - Property and Equipment	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	3. At June 30, 2022 September 30, 2021, Estimated Useful June 30, September 30, Life (years) 2022 2021 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease 8,983 8,983 Computer equipment 3 14,416 14,416 Lab equipment 5 1,000 1,000 33,756 33,756 Less – accumulated depreciation 30,913 28,516 Property and equipment, net $ 2,843 $ 5,240 For the three June 30, 2022 2021, nine June 30, 2022 2021,	3. At September 30, 2021 2020, ​ ​ ​Estimated ​ ​ ​ ​ ​ ​ ​ Useful September 30, September 30, ​ Life (years) 2021 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Furniture and fixtures 5 ​ $ 9,357 ​ $ 9,357 Leasehold improvements Life of Lease ​ $ 8,983 ​ $ 8,983 Computer equipment 3 ​ $ 14,416 ​ $ 11,141 Lab equipment 5 ​ $ 1,000 ​ $ 1,000 ​ ​ 33,756 ​ 30,481 Less - accumulated depreciation ​ 28,516 ​ 25,929 Property and equipment, net ​ $ 5,240 ​ $ 4,552 ​ For the years ended September 30, 2021 2020

Note 4 - Income Taxes

Note 4 - Income Taxes	12 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	4. The principal components of the Company’s net deferred tax assets consisted of the following at September 30: ​ ​ ​ ​ ​ ​ 2021 2020 Net operating loss carryforwards ​ $ 10,022,020 ​ $ 8,451,214 Capitalized expenditures ​ 1,703,849 ​ 1,782,185 Research and experimentation credit carryforwards ​ 946,158 ​ 928,734 Stock based compensation ​ 2,352,432 ​ 2,321,519 Property and Equipment ​ 2,740 ​ 3,152 Accrued expenses ​ 57,812 ​ 18,518 Inventory allowance 62,946 16,497 Gross deferred tax assets ​ 15,147,957 ​ 13,521,819 Deferred tax asset valuation allowance ​ (15,147,957 ) ​ (13,521,819 ​ ​ ​ ​ Net deferred tax assets ​ $ - ​ $ - ​ The provision (benefit) for income taxes differs from the tax computed with the statutory federal income tax rate as follows: ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 Expected income tax (benefit) at federal statutory rate 21.00 % 21.00 % ​ ​ ​ ​ ​ ​ Increase/(Decrease) due to: ​ State Taxes - Net of federal benefit 5.80 % 7.08 % ​ ​ ​ ​ ​ ​ Permanent Differences: ​ Key man life insurance (0.01 )% (0.01 )% R&D, taken as a credit (0.29 )% (0.51 )% Adjustment to fair value of derivative 0.37 % 3.04 % PPP Loan Forgiveness 0.60 % 0.00 % Other ​ (1.41 )% 0.51 % Change in Valuation Allowance (26.06 )% (31.11 )% Total Income Tax Provision / Benefit - % - % ​ As of September 30, 2021 2020, may 2018 2026. December 31, 2017 September 30, 2021 2020, September 30, 2021 2020, may 2028. As of September 30, 2021 2020, may 2030. September 30, 2021 2020, may 2023. As the Company has not September 30, 2021 2020 not 740, Income Taxes 2021 2020 The Company experienced an ownership change as a result of the Merger described in Note 1, 382 382 not As of September 30, 2021, September 30, 2021, 2020, 2019 2018. 2010 2020 The Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted on March 27, 2020. September 30, 2021

Note 5 - Inventories

Note 5 - Inventories	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	4 INVENTORIES Inventories consist of the following: June 30, September 30, 2022 2021 Finished goods $ — $ 249,571 Goods-in-process 1,428,264 844,194 Total $ 1,428,264 $ 1,093,765 The Company capitalizes inventory that has been produced for commercial sale and has been determined to have a probable future economic benefit. The determination of whether or not	5 INVENTORIES Inventories consist of the following: ​ ​ September 30, September 30, ​ ​ 2021 ​ 2020 Finished Goods ​ $ 249,571 ​ $ - Goods-in-process 844,194 967,993 Total ​ $ 1,093,765 ​ $ 967,993 ​ The Company capitalizes inventory that has been produced for commercial sale and has been determined to have a probable future economic benefit. The determination of whether or not

Note 6 - Registered Direct Offe

Note 6 - Registered Direct Offerings	12 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note, Direct Offerings [Text Block]	6. On September 30, 2016, October 20, 2016 ( may On February 24, 2017, “2017 6 “2017 2017 “2017 2017 2017 fifth “2017 2017 “2017 On July 2, 2018, “2018 “2018 2018 “2018 2018 2018 fifth “2018 2018 On May 12, 2019, "2019 "2019 2019 "2019 2019 one fifth 2019 2019 "2019 During the years ended September 30, 2021 2020 September 30, 2021, may

Note 7 - Derivative Liabilities

Note 7 - Derivative Liabilities	12 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Derivative Liabilities [Text Block]	7. The Company accounted for the Series F Warrants relating to the 2017 2018 2019 815 10, Derivatives and Hedging may not ​ On the respective closing dates, the Series F, Series G and Series H derivative liabilities were recorded at an aggregate fair value of $1,628,113. Given that the fair value of the derivative liabilities were less than the net proceeds, the remaining proceeds were allocated to Common Stock and additional-paid-in-capital. During the fiscal years ended September 30, 2021 2020, ​ ​ ​ ​ ​ Fair Value Measurements Using Significant Unobservable Inputs - September 30, 2021 ​ ​ ​ (Level 3) Series F Series G Series H Beginning balance at September 30, 2020 $ 1,000,000 $ 748,275 $ 568,144 ​ ​ ​ ​ Issuances - ​- - ​ ​ ​ ​ Adjustments to estimated fair value - ​- (108,944 ​ ​ ​ ​ Ending balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Fair Value Measurements Using Significant Unobservable Inputs - September 30, 2020 ​ ​ ​ ​ ​ (Level 3) ​ Series F ​ Series G ​ Series H Beginning balance at September 30, 2019 ​ $ 1,000,000 ​ $ 748,275 ​ $ 1,247,415 ​ ​ ​ ​ Issuances ​ - ​ - ​ - ​ ​ ​ ​ Adjustments to estimated fair value ​ - ​ - ​ (679,271 ​ ​ ​ Ending balance at September 30, 2020 ​ $ 1,000,000 ​ $ 748,275 ​ $ 568,144 ​ The derivative liabilities were valued as of September 30, 2021 ​ Series F Series G Series H Closing price per share of common stock $ 0.12 $ 0.12 $ 0.12 Exercise price per share $ 0.75 $ 0.7 $ 0.4 Expected volatility 90.28 % 87.4 % 86.59 % Risk-free interest rate 0.04 % 0.19 % 0.41 % Dividend yield — — — Remaining expected term of underlying securities (years) 0.34 1.7 2.58 The derivative liabilities were valued as of September 30, 2020 ​ Series F Series G Series H Closing price per share of common stock $ 0.17 $ 0.17 $ 0.17 Exercise price per share $ 0.75 $ 0.7 $ 0.4 Expected volatility 84.17 % 83.31 % 82.24 % Risk-free interest rate 0.13 % 0.15 % 0.22 % Dividend yield — — — Remaining expected term of underlying securities (years) 1.35 2.71 3.6 ​

Note 8 - October 2019 Registere

Note 8 - October 2019 Registered Direct Offering	12 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders Equity Note Direct Offering 2019 October [Text Block]	8. OCTOBER 2019 On October 16, 2019, “October 2019 7 “October 2019 2019 “October 2019 October 2019 one fifth “October 2019 October 2019 “October 2019 October 18, 2019, five The gross proceeds to Arch from the October 2019 October 18, 2019, We engaged H.C. Wainwright (“Wainwright”) as our exclusive institutional investor placement agent in connection with the October October 10, 2019, During the year ended September 30, 2021, September 30, 2021, may Common Stock At October 18, 2019 October 2019 Equity Value of Warrants The Company accounted for the Series I Warrants and the Placement Agent Warrants relating to the aforementioned October 2019 815 40, Derivatives and Hedging

Note 9 - 2021 Registered Direct

Note 9 - 2021 Registered Direct Offering	12 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders Equity Note Direct Offering 2021 [Text Block]	​9. 2021 On February 11, 2021, “2021 “2021 2021 “2021 February 8, 2021, 2021 one 2 The Placement Agent 2 2 The 2021 2021 February 11, 2022; may The number of shares of the Company’s Common Stock into which each of the Series K Warrants is exercisable and the exercise price therefore are subject to adjustment, as set forth in the Series K Warrants, including adjustments for stock subdivisions or combinations (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise). During the the fiscal year ended September 30, 2021, 2 June 30, 2021, may Common Stock On February 17, 2021 2021 Equity Value of Warrants The Company accounted for the Series K Warrants and the Placement Agent 2 February 2021 815 40, Derivatives and Hedging 2

Note 10 - Convertible Notes

Note 10 - Convertible Notes	12 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	10. On June 4, 2020 November 6, 2020, 1 1” 2 2” 1 2 June 30, 2023 November 30, 2023, 1 2 three 3 1 2 not 1 2 fifteen thirty-five ten twelve ten On June 3, 2020, June 4, 2020, November 6, 2020, one thirty On June 22, 2020, June 22, 2020, During the fiscal years ended September 30, 2021 2020, $18,000,respectively.

Note 11- Payroll Protection Pro

Note 11- Payroll Protection Program Loan	12 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Payroll Protection Program Loan [Text Block]	11. On April 25, 2020, The PPP Loan had a two The PPP Note contains customary events of default relating to, among other things, payment defaults, providing materially false and misleading representations to the SBA or Lender, or breaching the terms of the PPP Loan documents. The occurrence of an event of default may Under the terms of the CARES Act, PPP Loan recipients can apply for and be granted forgiveness for all or a portion of the loan granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. However, no November 2020, May 28, 2021, September 30, 2021,

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	5. 2013 On June 18, 2013, 2013 2013 2013 September 30, 2021, options Restricted Stock may one two 2013 first 2014, 2013 3,000,000 four Board October 1, 2021, 2013Plan The exercise price of each option is equal to the closing price of a share of the Company’s Common Stock on the date of grant. Share-Based Awards During the nine June 30, 2022, 2013 . Share-based compensation expense for awards granted during the nine June 30, 2022 Common Stock Options Stock compensation activity under the 2013 nine June 30, 2022 Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Awarded 675,000 0.06 — — Forfeited/Cancelled (3,083,818 ) 0.33 — — Outstanding at June 30, 2022 22,490,196 0.28 1.47 — Vested at June 30, 2022 19,135,976 0.31 1.70 — Vested and expected to vest at June 30, 2022 22,490,196 0.28 1.47 — As of June 30, 2022, 2013 Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the three June 30, 2022 2021 three June 30, 2022 2021, Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the nine June 30, 2022 2021 nine June 30, 2022 2021, nine June 30, 2022 2021, As of June 30, 2022, 2013 Restricted Stock Restricted Stock activity under the 2013 nine June 30, 2022 2021, Nine Months Ended June 30, 2022 June 30, 2021 Non Vested at September 30, 2021 and 2020 450,000 — Awarded — 550,000 Vested (275,000 ) (550,000 ) Forfeited — — Non Vested at June 30, 2022 and 2021 175,000 — The weighted average Restricted Stock award date fair value information for the nine June 30, 2022 2021 Nine Months Ended June 30, 2022 June 30, 2021 Non Vested at September 30, 2021 and 2020 $ 0.10 $ — Awarded — 0.19 Vested (0.10 ) (0.19 ) Forfeited — — Non Vested at June 30, 2022 and 2021 $ 0.10 $ — For the three June 30, 2022 2021, nine June 30, 2022 2021,	12. 2013 On June 18, 2013, 2013 “2013 2013 September 30, 2021, may one two 2013 first 2014, 2013 four 4 October 1, 2020, As of September 30, 2021, Share-based awards During the year ended September 30, 2021, 2013 . Share-based compensation expense for awards granted during the year ended September 30, 2021 September 30, 2021; Common Stock Options Stock compensation activity under the 2013 September 30, 2021 ​ ​ ​ ​ ​ Weighted ​ Average ​Weighted ​ ​ Option ​ Average ​ Remaining Aggregate ​ ​ Shares ​ Exercise ​ Contractual Intrinsic ​ ​ Outstanding ​ Price ​ Term (years) Value Outstanding at September 30, 2020 18,248,346 ​ $ 0.36 2.59 $ 79,330 Awarded 7,375,000 ​ $ 0.12 - - Forfeited/Cancelled (724,332 ) ​ $ 0.44 - - Outstanding at September 30, 2021 24,899,014 ​ $ 0.29 1.83 $ 140,151 Vested at September 30, 2021 18,814,908 ​ $ 0.35 2.17 $ 17,122 Vested and expected to vest at September 30, 2021 24,899,014 ​ $ 0.29 1.83 $ 140,151 ​ As of September 30, 2021, 2013 September 30, 2021 2020 September 30, 2021 2020, During the years ended September 30, 2021 2020, 2013 September 30, 2021 2020, 2013 As of September 30, 2021, 2013 Restricted Stock On October 14, 2020, 2013 January 27, 2021, 2013 July 30, 2021, 2013 January 12, 2022, July 12, 2022 January 12, 2023. September 27, 2021, 2013 1/12 twelve On July 19, 2018, 2013 second 2013 September 30, 2021, Restricted stock activity in shares under the 2013 September 30, 2021 2020 ​ ​ ​ ​ ​ ​ ​ 2021 2020 Non Vested at September 30, 2020 and 2019 - 965,000 Awarded 1,000,000 - Vested (550,000 ) (965,000 ) Forfeited - - Non Vested at September 30, 2021 and 2020 450,000 - ​ The weighted average restricted stock award date fair value information for the years ended September 30, 2021 2019 ​ ​ ​ ​ ​ ​ ​ ​ 2021 ​ 2020 Non Vested at September 30, 2020 and 2019 ​ $ - ​ $ 0.43 Awarded ​ 0.13 ​ - Vested ​ (0.16 ) ​ (0.43 ) Forfeited ​ - ​ - Non Vested at September 30, 2021 and 2020 ​ $ 0.10 ​ $ - ​ For the years ended September 30, 2021 2020 September 30, 2021, 2013

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	12 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	13. In the ordinary course of business, the Company enters into various agreements containing standard indemnification provisions. The Company’s indemnification obligations under such provisions are typically in effect from the date of execution of the applicable agreement through the end of the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. As of September 30, 2021 2020, no From time to time, the Company may MIT Licensing Agreement In December 2007, not In exchange for the licenses granted in the agreement, the Company has paid MIT license maintenance fees and patent prosecution costs. The Company paid license maintenance fees of $50,000 to MIT in the fiscal years ended September 30, 2021 2020. September 30, 2021 2020, January 1 December 31. may The Company is obligated to indemnify MIT and related parties from losses arising from claims relating to the exercise of any rights granted to the Company under the license, with certain exceptions. The maximum potential amount of future payments the Company could be required to make under this provision is unlimited. The Company considers there to be a low performance risk as of September 30, 2021. The agreement expires upon the expiration or abandonment of all patents that are issued and licensed to the Company by MIT under such agreement. The Company expects that patents will be issued from presently pending U.S. and foreign patent applications. Any such patent will have a term of 20 years from the filing date of the underlying application. MIT may not not may six Leases The Company's corporate offices are located in Framingham, MA. During July 2017, three October 1, 2017 September 30, 2020 first second third August 2020, September 30, 2021 $42,000. October 2021 six March 31, 2022 September 30, 2021 2020, $0 $39,000,

Note 14 - Risks and Uncertainti

Note 14 - Risks and Uncertainties - COVID-19	12 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Unusual or Infrequent Items, or Both, Disclosure [Text Block]	14. 19 The Company sources its materials and services for its products and product candidates from facilities in areas impacted or which may may may

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Description of Business	9 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Arch Therapeutics, Inc. (together with its subsidiary, the “ Company Arch September 16, 2009, June 26, 2013, Merger ABS Merger Sub ABS was incorporated under the laws of the Commonwealth of Massachusetts on March 6, 2006, April 7, 2008, In the first 2021, first AC5® Common Stock warrants The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its potential products. However, there can be no not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“ US GAAP Although the Company believes that the disclosures in these unaudited interim consolidated financial statements are adequate to make the information presented not SEC 10 September 30, 2021, December 17, 2021 ( Annual Report For a complete summary of the Company’s significant accounting policies, please refer to Note 2 8 no nine June 30, 2022. Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three June 30, 2022 September 30, 2021. Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not FASB ASC 360, Property, Plant and Equipment three nine June 30, 2022 2021 not Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s lease does not Income Taxes In accordance with FASB ASC Topic 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not Revenue In accordance with FASB ASC Topic 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third Cost of Revenue Cost of revenue includes product costs, warehousing, overhead allocation and royalty expense. Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation ASC 718 718, Black-Scholes Model The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the Common Stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99, no Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At June 30, 2022 September 30, 2021, 10 Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging ASC 815 no Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product(s) and eventually attaining and maintaining profitable operations. As of the date of issuance of the accompanying consolidated financial statements , the Company will be required to raise additional capital, obtain alternative means of financial support, or both, in order to continue to fund operations, and therefore there is substantial doubt about the Company’s ability to continue as a going concern. The Company expects to incur substantial expenses into the foreseeable future for the research, development and commercialization of its current and potential other products. In addition, the Company will require additional financing in order to seek to license or acquire new assets, research and develop any potential patents and the related compounds, and obtain any further intellectual property that the Company may APIs AC5® June 28, 2018 (“ 2018 2018 not 2018 20% 6 2018 The continued spread of coronavirus and geopolitical conflicts, including the recent war in Ukraine, as well as uncertain market conditions, may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not	2. The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“ US GAAP Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Recently Issued and Adopted Accounting Guidance Accounting Standards Update (ASU) 2018 13, 820 August 2018. 820. December 15, 2019. 2018 13 first 2021, ASU 2020 06, 470 02 815 40 August 2020. December 15, 2023. not Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three September 30, 2021 2020. Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not 360, Property, Plant and Equipment September 30, 2021 2020 not Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use (“ROU“) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our lease does not September 30, 2021 2020, September 30, 2021 2020, Income Taxes In accordance with FASB ASC 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not Revenue In accordance with FASB ASC 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third Cost of Revenues Cost of revenues includes product costs, warehousing, overhead allocation and royalty expenses. Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation 718” 718, The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99 no Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At September 30, 2021 2020, Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging no Financial Statement Reclassification Certain balances in the prior year consolidated financial statements have been reclassified for comparison purposes to conform to the presentation in the current period consolidated financial statements. Subsequent Events The Company evaluated all events or transactions through December 16, 2021, no 15 Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product and eventually attaining and maintaining profitable operations. In particular, as of September 30, 2021, may AC5® February 20, 2017 ( “2017 June 28, 2018 ( “2018 2017 2018 not three 2017 2018 20% 2017 2018 2021 2021 February 11, 2022; may may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment (10Q)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	3. At June 30, 2022 September 30, 2021, Estimated Useful June 30, September 30, Life (years) 2022 2021 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease 8,983 8,983 Computer equipment 3 14,416 14,416 Lab equipment 5 1,000 1,000 33,756 33,756 Less – accumulated depreciation 30,913 28,516 Property and equipment, net $ 2,843 $ 5,240 For the three June 30, 2022 2021, nine June 30, 2022 2021,	3. At September 30, 2021 2020, ​ ​ ​Estimated ​ ​ ​ ​ ​ ​ ​ Useful September 30, September 30, ​ Life (years) 2021 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Furniture and fixtures 5 ​ $ 9,357 ​ $ 9,357 Leasehold improvements Life of Lease ​ $ 8,983 ​ $ 8,983 Computer equipment 3 ​ $ 14,416 ​ $ 11,141 Lab equipment 5 ​ $ 1,000 ​ $ 1,000 ​ ​ 33,756 ​ 30,481 Less - accumulated depreciation ​ 28,516 ​ 25,929 Property and equipment, net ​ $ 5,240 ​ $ 4,552 ​ For the years ended September 30, 2021 2020

Note 4 - Inventories

Note 4 - Inventories	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	4 INVENTORIES Inventories consist of the following: June 30, September 30, 2022 2021 Finished goods $ — $ 249,571 Goods-in-process 1,428,264 844,194 Total $ 1,428,264 $ 1,093,765 The Company capitalizes inventory that has been produced for commercial sale and has been determined to have a probable future economic benefit. The determination of whether or not	5 INVENTORIES Inventories consist of the following: ​ ​ September 30, September 30, ​ ​ 2021 ​ 2020 Finished Goods ​ $ 249,571 ​ $ - Goods-in-process 844,194 967,993 Total ​ $ 1,093,765 ​ $ 967,993 ​ The Company capitalizes inventory that has been produced for commercial sale and has been determined to have a probable future economic benefit. The determination of whether or not

Note 5 - Stock-based Compensati

Note 5 - Stock-based Compensation	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	5. 2013 On June 18, 2013, 2013 2013 2013 September 30, 2021, options Restricted Stock may one two 2013 first 2014, 2013 3,000,000 four Board October 1, 2021, 2013Plan The exercise price of each option is equal to the closing price of a share of the Company’s Common Stock on the date of grant. Share-Based Awards During the nine June 30, 2022, 2013 . Share-based compensation expense for awards granted during the nine June 30, 2022 Common Stock Options Stock compensation activity under the 2013 nine June 30, 2022 Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Awarded 675,000 0.06 — — Forfeited/Cancelled (3,083,818 ) 0.33 — — Outstanding at June 30, 2022 22,490,196 0.28 1.47 — Vested at June 30, 2022 19,135,976 0.31 1.70 — Vested and expected to vest at June 30, 2022 22,490,196 0.28 1.47 — As of June 30, 2022, 2013 Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the three June 30, 2022 2021 three June 30, 2022 2021, Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the nine June 30, 2022 2021 nine June 30, 2022 2021, nine June 30, 2022 2021, As of June 30, 2022, 2013 Restricted Stock Restricted Stock activity under the 2013 nine June 30, 2022 2021, Nine Months Ended June 30, 2022 June 30, 2021 Non Vested at September 30, 2021 and 2020 450,000 — Awarded — 550,000 Vested (275,000 ) (550,000 ) Forfeited — — Non Vested at June 30, 2022 and 2021 175,000 — The weighted average Restricted Stock award date fair value information for the nine June 30, 2022 2021 Nine Months Ended June 30, 2022 June 30, 2021 Non Vested at September 30, 2021 and 2020 $ 0.10 $ — Awarded — 0.19 Vested (0.10 ) (0.19 ) Forfeited — — Non Vested at June 30, 2022 and 2021 $ 0.10 $ — For the three June 30, 2022 2021, nine June 30, 2022 2021,	12. 2013 On June 18, 2013, 2013 “2013 2013 September 30, 2021, may one two 2013 first 2014, 2013 four 4 October 1, 2020, As of September 30, 2021, Share-based awards During the year ended September 30, 2021, 2013 . Share-based compensation expense for awards granted during the year ended September 30, 2021 September 30, 2021; Common Stock Options Stock compensation activity under the 2013 September 30, 2021 ​ ​ ​ ​ ​ Weighted ​ Average ​Weighted ​ ​ Option ​ Average ​ Remaining Aggregate ​ ​ Shares ​ Exercise ​ Contractual Intrinsic ​ ​ Outstanding ​ Price ​ Term (years) Value Outstanding at September 30, 2020 18,248,346 ​ $ 0.36 2.59 $ 79,330 Awarded 7,375,000 ​ $ 0.12 - - Forfeited/Cancelled (724,332 ) ​ $ 0.44 - - Outstanding at September 30, 2021 24,899,014 ​ $ 0.29 1.83 $ 140,151 Vested at September 30, 2021 18,814,908 ​ $ 0.35 2.17 $ 17,122 Vested and expected to vest at September 30, 2021 24,899,014 ​ $ 0.29 1.83 $ 140,151 ​ As of September 30, 2021, 2013 September 30, 2021 2020 September 30, 2021 2020, During the years ended September 30, 2021 2020, 2013 September 30, 2021 2020, 2013 As of September 30, 2021, 2013 Restricted Stock On October 14, 2020, 2013 January 27, 2021, 2013 July 30, 2021, 2013 January 12, 2022, July 12, 2022 January 12, 2023. September 27, 2021, 2013 1/12 twelve On July 19, 2018, 2013 second 2013 September 30, 2021, Restricted stock activity in shares under the 2013 September 30, 2021 2020 ​ ​ ​ ​ ​ ​ ​ 2021 2020 Non Vested at September 30, 2020 and 2019 - 965,000 Awarded 1,000,000 - Vested (550,000 ) (965,000 ) Forfeited - - Non Vested at September 30, 2021 and 2020 450,000 - ​ The weighted average restricted stock award date fair value information for the years ended September 30, 2021 2019 ​ ​ ​ ​ ​ ​ ​ ​ 2021 ​ 2020 Non Vested at September 30, 2020 and 2019 ​ $ - ​ $ 0.43 Awarded ​ 0.13 ​ - Vested ​ (0.16 ) ​ (0.43 ) Forfeited ​ - ​ - Non Vested at September 30, 2021 and 2020 ​ $ 0.10 ​ $ - ​ For the years ended September 30, 2021 2020 September 30, 2021, 2013

Note 6 - Registered Direct Of_2

Note 6 - Registered Direct Offerings That Created Derivative Liabilities	9 Months Ended
	Jun. 30, 2022
Registered Direct Offerings [Member]
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	6. On September 30, 2016, October 20, 2016 Shelf Registration Statement may On February 20, 2017, 2017 six 2017 2017 2017 2017 Series F Warrant fifth 2017 2017 2017 On June 28, 2018, 2018 eight 2018 2018 2018 2018 Series G Warrant fifth 2018 2018 2018 On May 12, 2019, 2019 five 2019 2019 2019 2019 one Series H Warrant fifth 2019 2019 2019 During the three nine June 30, 2022 2021, June 30, 2022, 6,802,500 may June 30, 2022, may three nine June 30, 2022,

Note 7 - Derivative Liabiliti_2

Note 7 - Derivative Liabilities (10Q)	9 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	7. The Company accounted for the Series F Warrants, the Series G Warrants and the Series H Warrants in accordance with ASC 815 10. may Minimum not On the respective closing dates, the derivative liabilities related to the Series F Warrants, Series G Warrants and Series H Warrants were recorded at an aggregate fair value of $1,628,113. Given that the fair value of the derivative liabilities was less than the net proceeds, the remaining proceeds were allocated to Common Stock and additional-paid-in-capital. During the three June 30, 2022 2021, nine June 30, 2022 2021, Fair Value Measurements Using Significant Unobservable Inputs - Nine Months Ended June 30, 2022 (Level 3) Series F Series G Series H Beginning balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Issuances — — — Adjustments to estimated fair value (1,000,000 ) — — Ending balance at June 30, 2022 $ — $ 748,275 $ 459,200 Fair Value Measurements Using Significant Unobservable Inputs Year Ended September 30, 2021 (Level 3) Series F Series G Series H Beginning balance at September 30, 2020 $ 1,000,000 $ 748,275 $ 568,144 Issuances — — — Adjustments to estimated fair value — — (108,944 ) Ending balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 The derivative liabilities were valued as of June 30, 2022 Series G Series H Closing price per share of Common Stock $ 0.046 $ 0.046 Exercise price per share $ 0.70 $ 0.40 Expected volatility 106.18 % 95.85 % Risk-free interest rate 2.80 % 2.92 % Dividend yield — — Remaining expected term of underlying securities (years) 0.94 1.83 The derivative liabilities were valued as of September 30, 2021 Series F Series G Series H Closing price per share of Common Stock $ 0.12 $ 0.12 $ 0.12 Exercise price per share $ 0.75 $ 0.70 $ 0.40 Expected volatility 90.28 % 87.40 % 86.59 % Risk-free interest rate 0.04 % 0.19 % 0.41 % Dividend yield — — — Remaining expected term of underlying securities (years) 0.34 1.70 2.58

Note 8 - October 2019 Registe_2

Note 8 - October 2019 Registered Direct Offering	9 Months Ended
	Jun. 30, 2022
October 2019 Registered Direct Offering [Member]
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. OCTOBER 2019 On October 16, 2019, October 2019 seven October 2019 2019 October 2019 Financing October 2019 Series I Warrant fifth October 2019 Shares October 18, 2019, 14,285,714 Placement Agent Warrants five The gross proceeds to the Company from the October 2019 October 18, 2019, The Company engaged H.C. Wainwright as its exclusive institutional investor placement agent (the “ Placement Agent October 2019 October 10, 2019 ( 2019 $2.5 $158,000. During the nine June 30, 2022 2021, June 30, 2022, may Common Stock On October 18, 2019, October 2019 14,285,714 Equity Value of Warrants The Company accounted for the Series I Warrants and the Placement Agent Warrants relating to the aforementioned October 2019 815 40.

Note 9 - 2021 Registered Dire_2

Note 9 - 2021 Registered Direct Offering	9 Months Ended
	Jun. 30, 2022
The 2021 Registered Direct Offering [Member]
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. 2021 On February 11, 2021, 2021 2021 2021 Shares Series K Warrants Warrant Shares 2021 February 8, 2021 ( 2021 2021 one 2021 2021 Placement Agent 2 2 2 2021 The 2021 2021 February 11, 2022; provided, however, may The number of shares of the Company’s Common Stock into which each of the Series K Warrants is exercisable and the exercise price therefore are subject to adjustment, as set forth in the Series K Warrants, including adjustments for stock subdivisions or combinations (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise). During the nine June 30, 2022, 2 June 30, 2022, may Common Stock On February 17, 2021, 2021 43,125,004 Equity Value of Warrants The Company accounted for the Series K Warrants and the Placement Agent 2 February 2021 815 40, Derivatives and Hedging 2

Note 10 - Series 1 and Series 2

Note 10 - Series 1 and Series 2 Convertible Notes	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]		10. On June 4, 2020 November 6, 2020, 1 1” 2 2” 1 2 June 30, 2023 November 30, 2023, 1 2 three 3 1 2 not 1 2 fifteen thirty-five ten twelve ten On June 3, 2020, June 4, 2020, November 6, 2020, one thirty On June 22, 2020, June 22, 2020, During the fiscal years ended September 30, 2021 2020, $18,000,respectively.
Series 1 & 2 Convertible Notes [Member]
Notes to Financial Statements
Debt Disclosure [Text Block]	10. 1 2 On June 4, 2020 November 6, 2020, 1 Series 1 2 Series 2 1 Convertible Notes 1 2 June 30, 2023 November 30, 2023, three not Conversion Price 1 2 Holder VWAP fifteen In-Kind Note Repayment provided, however, thirty-five ten twelve ten March 31, 2022, thirty-five sixty On June 3, 2020, Agreement Majority Holder s Series D Warrants June 4, 2020, 1 Series J Warrants November 6, 2020, one thirty On June 22, 2020, Keyes Sulat Agreement Trust June 22, 2020, one During the three June 30, 2022 2021, nine June 30, 2022 2021,

Note 11 - Advances from Investo

Note 11 - Advances from Investors	9 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Senior Secured Convertible Notes, Warrants and Common Stock, Prefunding [Text Block]	11. As of June 30, 2022, 14 Terrence Norchi, the Company’s President and Chief Executive Officer, Michael Abrams, the Company’s Chief Financial Officer, and Laurence Hicks, a member of the Company’s board of directors, through Drake Partners LLC, participated in the Convertible Notes Offering for an aggregate of $80,000.

Note 12 - Payroll Protection Pr

Note 12 - Payroll Protection Program Loan	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]		10. On June 4, 2020 November 6, 2020, 1 1” 2 2” 1 2 June 30, 2023 November 30, 2023, 1 2 three 3 1 2 not 1 2 fifteen thirty-five ten twelve ten On June 3, 2020, June 4, 2020, November 6, 2020, one thirty On June 22, 2020, June 22, 2020, During the fiscal years ended September 30, 2021 2020, $18,000,respectively.
Paycheck Protection Program Loan [Member]
Notes to Financial Statements
Debt Disclosure [Text Block]	12. On April 25, 2020, PPP Note PPP Loan PPP CARES Act SBA Lender The PPP Loan had a two 1.00% not $20,000 The PPP Note contained customary events of default relating to, among other things, payment defaults, providing materially false and misleading representations to the SBA or Lender, or breaching the terms of the PPP Loan documents. The occurrence of an event of default would have resulted in the immediate repayment of all amounts outstanding, collection of all amounts owing from the Company, or filing suit and obtaining judgment. Under the terms of the CARES Act, PPP Loan recipients can apply for and be granted forgiveness for all or a portion of the loan granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. During November 2020, May 28, 2021, The SBA reserves the right to audit any PPP loan, regardless of size. These audits may six

Note 13 - Risks and Uncertainti

Note 13 - Risks and Uncertainties - COVID-19 and Geopolitical Conflicts	9 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
COVID-19 Disclsoure [Text Block]	13. COVID- 19 The Company sources its materials and services for its products and product candidates from facilities in areas impacted or which may may may

Note 14 - Subsequent Events

Note 14 - Subsequent Events	9 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	14. SUBSEQUENT EVENTS The Company evaluated all events or transactions through August 11, 2022, no On July 7, 2022, SPA Investors 2022 2022 2022 2022 Warrant Shares Inducement Shares 2022 2022 2022 Convertible Notes Offering 2022 2022 11 July 6, 2022 ( Closing Date The Company retained a placement agent in connection with the private placement of $2.4 million of the 2022 In addition, as a part of the Convertible Notes Offering, certain holders (the “ Series Holders 1 2 Series Notes 2022 Exchanged Notes 2022 Further, in connection with the 2022 February 15, 2023 2022 2022 2022 2022 2022

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation.	Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates.	Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]		Recently Issued and Adopted Accounting Guidance Accounting Standards Update (ASU) 2018 13, 820 August 2018. 820. December 15, 2019. 2018 13 first 2021, ASU 2020 06, 470 02 815 40 August 2020. December 15, 2023. not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three June 30, 2022 September 30, 2021.	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three September 30, 2021 2020.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors.	Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred.	Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not FASB ASC 360, Property, Plant and Equipment three nine June 30, 2022 2021 not	Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not 360, Property, Plant and Equipment September 30, 2021 2020 not
Lessee, Leases [Policy Text Block]	Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s lease does not	Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use (“ROU“) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our lease does not September 30, 2021 2020, September 30, 2021 2020,
Income Tax, Policy [Policy Text Block]	Income Taxes In accordance with FASB ASC Topic 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not	Income Taxes In accordance with FASB ASC 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not
Revenue from Contract with Customer [Policy Text Block]	Revenue In accordance with FASB ASC Topic 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third	Revenue In accordance with FASB ASC 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third
Cost of Goods and Service [Policy Text Block]	Cost of Revenue Cost of revenue includes product costs, warehousing, overhead allocation and royalty expense.	Cost of Revenues Cost of revenues includes product costs, warehousing, overhead allocation and royalty expenses.
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred.	Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred.
Share-Based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation ASC 718 718, Black-Scholes Model The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the Common Stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99, no	Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation 718” 718, The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99 no
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At June 30, 2022 September 30, 2021, 10	Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At September 30, 2021 2020,
Derivatives, Reporting of Derivative Activity [Policy Text Block]		Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging no
Financial Statement Reclassification [Policy Text Block]		Financial Statement Reclassification Certain balances in the prior year consolidated financial statements have been reclassified for comparison purposes to conform to the presentation in the current period consolidated financial statements.
Subsequent Events, Policy [Policy Text Block]		Subsequent Events The Company evaluated all events or transactions through December 16, 2021, no 15
Going Concern Basis Of Accounting [Policy Text Block]		Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product and eventually attaining and maintaining profitable operations. In particular, as of September 30, 2021, may AC5® February 20, 2017 ( “2017 June 28, 2018 ( “2018 2017 2018 not three 2017 2018 20% 2017 2018 2021 2021 February 11, 2022; may may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not
Derivatives, Policy [Policy Text Block]	Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging ASC 815 no
Going Concern [Policy Text Block]	Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product(s) and eventually attaining and maintaining profitable operations. As of the date of issuance of the accompanying consolidated financial statements , the Company will be required to raise additional capital, obtain alternative means of financial support, or both, in order to continue to fund operations, and therefore there is substantial doubt about the Company’s ability to continue as a going concern. The Company expects to incur substantial expenses into the foreseeable future for the research, development and commercialization of its current and potential other products. In addition, the Company will require additional financing in order to seek to license or acquire new assets, research and develop any potential patents and the related compounds, and obtain any further intellectual property that the Company may APIs AC5® June 28, 2018 (“ 2018 2018 not 2018 20% 6 2018 The continued spread of coronavirus and geopolitical conflicts, including the recent war in Ukraine, as well as uncertain market conditions, may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment (Tables)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	Estimated Useful June 30, September 30, Life (years) 2022 2021 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease 8,983 8,983 Computer equipment 3 14,416 14,416 Lab equipment 5 1,000 1,000 33,756 33,756 Less – accumulated depreciation 30,913 28,516 Property and equipment, net $ 2,843 $ 5,240	​ ​ ​Estimated ​ ​ ​ ​ ​ ​ ​ Useful September 30, September 30, ​ Life (years) 2021 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Furniture and fixtures 5 ​ $ 9,357 ​ $ 9,357 Leasehold improvements Life of Lease ​ $ 8,983 ​ $ 8,983 Computer equipment 3 ​ $ 14,416 ​ $ 11,141 Lab equipment 5 ​ $ 1,000 ​ $ 1,000 ​ ​ 33,756 ​ 30,481 Less - accumulated depreciation ​ 28,516 ​ 25,929 Property and equipment, net ​ $ 5,240 ​ $ 4,552

Note 4 - Income Taxes (Tables)

Note 4 - Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	​ ​ ​ ​ ​ 2021 2020 Net operating loss carryforwards ​ $ 10,022,020 ​ $ 8,451,214 Capitalized expenditures ​ 1,703,849 ​ 1,782,185 Research and experimentation credit carryforwards ​ 946,158 ​ 928,734 Stock based compensation ​ 2,352,432 ​ 2,321,519 Property and Equipment ​ 2,740 ​ 3,152 Accrued expenses ​ 57,812 ​ 18,518 Inventory allowance 62,946 16,497 Gross deferred tax assets ​ 15,147,957 ​ 13,521,819 Deferred tax asset valuation allowance ​ (15,147,957 ) ​ (13,521,819 ​ ​ ​ ​ Net deferred tax assets ​ $ - ​ $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	​ ​ ​ ​ ​ ​ ​ 2021 2020 Expected income tax (benefit) at federal statutory rate 21.00 % 21.00 % ​ ​ ​ ​ ​ ​ Increase/(Decrease) due to: ​ State Taxes - Net of federal benefit 5.80 % 7.08 % ​ ​ ​ ​ ​ ​ Permanent Differences: ​ Key man life insurance (0.01 )% (0.01 )% R&D, taken as a credit (0.29 )% (0.51 )% Adjustment to fair value of derivative 0.37 % 3.04 % PPP Loan Forgiveness 0.60 % 0.00 % Other ​ (1.41 )% 0.51 % Change in Valuation Allowance (26.06 )% (31.11 )% Total Income Tax Provision / Benefit - % - %

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, September 30, 2022 2021 Finished goods $ — $ 249,571 Goods-in-process 1,428,264 844,194 Total $ 1,428,264 $ 1,093,765	​ September 30, September 30, ​ ​ 2021 ​ 2020 Finished Goods ​ $ 249,571 ​ $ - Goods-in-process 844,194 967,993 Total ​ $ 1,093,765 ​ $ 967,993

Note 7 - Derivative Liabiliti_3

Note 7 - Derivative Liabilities (Tables)	12 Months Ended
	Sep. 30, 2021
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	​ ​ ​ ​ Fair Value Measurements Using Significant Unobservable Inputs - September 30, 2021 ​ ​ ​ (Level 3) Series F Series G Series H Beginning balance at September 30, 2020 $ 1,000,000 $ 748,275 $ 568,144 ​ ​ ​ ​ Issuances - ​- - ​ ​ ​ ​ Adjustments to estimated fair value - ​- (108,944 ​ ​ ​ ​ Ending balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Fair Value Measurements Using Significant Unobservable Inputs - September 30, 2020 ​ ​ ​ ​ ​ (Level 3) ​ Series F ​ Series G ​ Series H Beginning balance at September 30, 2019 ​ $ 1,000,000 ​ $ 748,275 ​ $ 1,247,415 ​ ​ ​ ​ Issuances ​ - ​ - ​ - ​ ​ ​ ​ Adjustments to estimated fair value ​ - ​ - ​ (679,271 ​ ​ ​ Ending balance at September 30, 2020 ​ $ 1,000,000 ​ $ 748,275 ​ $ 568,144
Schedule Of Assumptions Used To Value Derivative Liability [Table Text Block]	Series F Series G Series H Closing price per share of common stock $ 0.12 $ 0.12 $ 0.12 Exercise price per share $ 0.75 $ 0.7 $ 0.4 Expected volatility 90.28 % 87.4 % 86.59 % Risk-free interest rate 0.04 % 0.19 % 0.41 % Dividend yield — — — Remaining expected term of underlying securities (years) 0.34 1.7 2.58 Series F Series G Series H Closing price per share of common stock $ 0.17 $ 0.17 $ 0.17 Exercise price per share $ 0.75 $ 0.7 $ 0.4 Expected volatility 84.17 % 83.31 % 82.24 % Risk-free interest rate 0.13 % 0.15 % 0.22 % Dividend yield — — — Remaining expected term of underlying securities (years) 1.35 2.71 3.6

Note 12 - Stock-based Compens_2

Note 12 - Stock-based Compensation (Tables)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Awarded 675,000 0.06 — — Forfeited/Cancelled (3,083,818 ) 0.33 — — Outstanding at June 30, 2022 22,490,196 0.28 1.47 — Vested at June 30, 2022 19,135,976 0.31 1.70 — Vested and expected to vest at June 30, 2022 22,490,196 0.28 1.47 —	​ ​ ​ ​ Weighted ​ Average ​Weighted ​ ​ Option ​ Average ​ Remaining Aggregate ​ ​ Shares ​ Exercise ​ Contractual Intrinsic ​ ​ Outstanding ​ Price ​ Term (years) Value Outstanding at September 30, 2020 18,248,346 ​ $ 0.36 2.59 $ 79,330 Awarded 7,375,000 ​ $ 0.12 - - Forfeited/Cancelled (724,332 ) ​ $ 0.44 - - Outstanding at September 30, 2021 24,899,014 ​ $ 0.29 1.83 $ 140,151 Vested at September 30, 2021 18,814,908 ​ $ 0.35 2.17 $ 17,122 Vested and expected to vest at September 30, 2021 24,899,014 ​ $ 0.29 1.83 $ 140,151
Nonvested Restricted Stock Shares Activity [Table Text Block]		​ ​ ​ ​ ​ ​ 2021 2020 Non Vested at September 30, 2020 and 2019 - 965,000 Awarded 1,000,000 - Vested (550,000 ) (965,000 ) Forfeited - - Non Vested at September 30, 2021 and 2020 450,000 -
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]		​ ​ ​ ​ ​ ​ ​ 2021 ​ 2020 Non Vested at September 30, 2020 and 2019 ​ $ - ​ $ 0.43 Awarded ​ 0.13 ​ - Vested ​ (0.16 ) ​ (0.43 ) Forfeited ​ - ​ - Non Vested at September 30, 2021 and 2020 ​ $ 0.10 ​ $ -

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment (10Q) (Tables)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	Estimated Useful June 30, September 30, Life (years) 2022 2021 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease 8,983 8,983 Computer equipment 3 14,416 14,416 Lab equipment 5 1,000 1,000 33,756 33,756 Less – accumulated depreciation 30,913 28,516 Property and equipment, net $ 2,843 $ 5,240	​ ​ ​Estimated ​ ​ ​ ​ ​ ​ ​ Useful September 30, September 30, ​ Life (years) 2021 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ Furniture and fixtures 5 ​ $ 9,357 ​ $ 9,357 Leasehold improvements Life of Lease ​ $ 8,983 ​ $ 8,983 Computer equipment 3 ​ $ 14,416 ​ $ 11,141 Lab equipment 5 ​ $ 1,000 ​ $ 1,000 ​ ​ 33,756 ​ 30,481 Less - accumulated depreciation ​ 28,516 ​ 25,929 Property and equipment, net ​ $ 5,240 ​ $ 4,552

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, September 30, 2022 2021 Finished goods $ — $ 249,571 Goods-in-process 1,428,264 844,194 Total $ 1,428,264 $ 1,093,765	​ September 30, September 30, ​ ​ 2021 ​ 2020 Finished Goods ​ $ 249,571 ​ $ - Goods-in-process 844,194 967,993 Total ​ $ 1,093,765 ​ $ 967,993

Note 5 - Stock-based Compensa_2

Note 5 - Stock-based Compensation (Tables)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Awarded 675,000 0.06 — — Forfeited/Cancelled (3,083,818 ) 0.33 — — Outstanding at June 30, 2022 22,490,196 0.28 1.47 — Vested at June 30, 2022 19,135,976 0.31 1.70 — Vested and expected to vest at June 30, 2022 22,490,196 0.28 1.47 —	​ ​ ​ ​ Weighted ​ Average ​Weighted ​ ​ Option ​ Average ​ Remaining Aggregate ​ ​ Shares ​ Exercise ​ Contractual Intrinsic ​ ​ Outstanding ​ Price ​ Term (years) Value Outstanding at September 30, 2020 18,248,346 ​ $ 0.36 2.59 $ 79,330 Awarded 7,375,000 ​ $ 0.12 - - Forfeited/Cancelled (724,332 ) ​ $ 0.44 - - Outstanding at September 30, 2021 24,899,014 ​ $ 0.29 1.83 $ 140,151 Vested at September 30, 2021 18,814,908 ​ $ 0.35 2.17 $ 17,122 Vested and expected to vest at September 30, 2021 24,899,014 ​ $ 0.29 1.83 $ 140,151
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Nine Months Ended June 30, 2022 June 30, 2021 Non Vested at September 30, 2021 and 2020 450,000 — Awarded — 550,000 Vested (275,000 ) (550,000 ) Forfeited — — Non Vested at June 30, 2022 and 2021 175,000 — Nine Months Ended June 30, 2022 June 30, 2021 Non Vested at September 30, 2021 and 2020 $ 0.10 $ — Awarded — 0.19 Vested (0.10 ) (0.19 ) Forfeited — — Non Vested at June 30, 2022 and 2021 $ 0.10 $ —

Note 7 - Derivative Liabiliti_4

Note 7 - Derivative Liabilities (10Q) (Tables)	9 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Fair Value Measurements Using Significant Unobservable Inputs - Nine Months Ended June 30, 2022 (Level 3) Series F Series G Series H Beginning balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Issuances — — — Adjustments to estimated fair value (1,000,000 ) — — Ending balance at June 30, 2022 $ — $ 748,275 $ 459,200 Fair Value Measurements Using Significant Unobservable Inputs Year Ended September 30, 2021 (Level 3) Series F Series G Series H Beginning balance at September 30, 2020 $ 1,000,000 $ 748,275 $ 568,144 Issuances — — — Adjustments to estimated fair value — — (108,944 ) Ending balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Series G Series H Closing price per share of Common Stock $ 0.046 $ 0.046 Exercise price per share $ 0.70 $ 0.40 Expected volatility 106.18 % 95.85 % Risk-free interest rate 2.80 % 2.92 % Dividend yield — — Remaining expected term of underlying securities (years) 0.94 1.83 Series F Series G Series H Closing price per share of Common Stock $ 0.12 $ 0.12 $ 0.12 Exercise price per share $ 0.75 $ 0.70 $ 0.40 Expected volatility 90.28 % 87.40 % 86.59 % Risk-free interest rate 0.04 % 0.19 % 0.41 % Dividend yield — — — Remaining expected term of underlying securities (years) 0.34 1.70 2.58

Note 2 - Summary Of Significa_3

Note 2 - Summary Of Significant Accounting Policies (Details Textual) - USD ($)	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Cash Equivalents, at Carrying Value, Total	$ 0	$ 0	$ 0
Operating Lease, Right-of-Use Asset		0	39,000
Operating Lease, Liability, Total		$ 0	$ 39,000

Note 3 - Property and Equipme_5

Note 3 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Depreciation, Total	$ 799	$ 799	$ 2,397	$ 1,788	$ 2,587	$ 6,926

Note 3 - Property and Equipme_6

Note 3 - Property and Equipment - Property and Equipment (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Property and equipment, gross	$ 33,756	$ 33,756	$ 30,481
Less - accumulated depreciation, Total	30,913	28,516	25,929
Property and equipment, net	$ 2,843	$ 5,240	4,552
Furniture and Fixtures [Member]
Estimated useful life (Year)	5 years	5 years
Property and equipment, gross	$ 9,357	$ 9,357	9,357
Leasehold Improvements [Member]
Property and equipment, gross	$ 8,983	$ 8,983	8,983
Computer Equipment [Member]
Estimated useful life (Year)	3 years	3 years
Property and equipment, gross	$ 14,416	$ 14,416	11,141
Technology Equipment [Member]
Estimated useful life (Year)		5 years
Property and equipment, gross		$ 1,000	$ 1,000

Note 4 - Income Taxes (Details

Note 4 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	$ 37,018,000	$ 31,119,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	36,033,000	30,737,000
Deferred Tax Assets, Tax Credit Carryforwards, Other	2,740	3,152
Deferred Tax Assets, Tax Credit Carryforwards, Research	946,158	928,734
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	1,626,000	1,459,000
Expire In 2026 [Member]
Deferred Tax Assets, Operating Loss Carryforwards, State and Local		21,750,000
Expire In 2028 [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Other	15,268,000	9,369,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	643,000	557,000
Expire In 2023 [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 384,000	$ 345,000

Note 4 - Income Taxes - Net Def

Note 4 - Income Taxes - Net Deferred Tax Assets (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Net operating loss carryforwards	$ 10,022,020	$ 8,451,214
Capitalized expenditures	1,703,849	1,782,185
Research and experimentation credit carryforwards	946,158	928,734
Stock based compensation	2,352,432	2,321,519
Property and Equipment	2,740	3,152
Accrued expenses	57,812	18,518
Inventory allowance	62,946	16,497
Gross deferred tax assets	15,147,957	13,521,819
Deferred tax asset valuation allowance	(15,147,957)	(13,521,819)
Net deferred tax assets	$ 0	$ 0

Note 4 - Income Taxes - Computa

Note 4 - Income Taxes - Computation of Provision (benefits) Income Taxes from Statutory Federal Income Tax Rate (Details)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Expected income tax (benefit) at federal statutory rate	21%	21%
Increase/(Decrease) due to:
State Taxes - Net of federal benefit	5.80%	7.08%
Permanent Differences:
Key man life insurance	(0.01%)	(0.01%)
R&D, taken as a credit	(0.29%)	(0.51%)
Adjustment to fair value of derivative	0.37%	3.04%
PPP Loan Forgiveness	0.60%	0%
Other	(1.41%)	0.51%
Change in Valuation Allowance	(26.06%)	(31.11%)
Total Income Tax Provision / Benefit	0%	0%

Note 5 - Inventories - Inventor

Note 5 - Inventories - Inventories (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Finished Goods		$ 249,571	$ 0
Goods-in-process		844,194	967,993
Total	$ 1,428,264	$ 1,093,765	$ 967,993

Note 6 - Registered Direct Of_3

Note 6 - Registered Direct Offerings (Details Textual)				12 Months Ended
	May 12, 2019 $ / shares shares	Jul. 02, 2018 $ / shares shares	Feb. 24, 2017 $ / shares shares	Sep. 30, 2021 shares	Sep. 30, 2016 USD ($)
Shelf Registration Statement, Maximum Amount Authorized | $					$ 50,000,000
Class Of Series F Warrant [Member]
Class of Warrant or Right, Exercised (in shares)				0
Class Of Warrant Or Right Acquired Upon Exercise (in shares)				5,591,664
Class Of Series G Warrant [Member]
Class Of Warrant Or Right Acquired Upon Exercise (in shares)				6,802,500
Class Of Series H Warrant [Member]
Class Of Warrant Or Right Acquired Upon Exercise (in shares)				8,615,384
Registered Direct Offering 2017 [Member]
Stock Issued During Period, Shares, New Issues (in shares)			10,166,664
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 0.60
Registered Direct Offering 2017 [Member] | Class Of Series F Warrant [Member]
Percentage of Warrants Per Unit			55
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.75
Registered Direct Offering 2018 [Member]
Stock Issued During Period, Shares, New Issues (in shares)		9,070,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares		$ 0.50
Number Of Accredited Investors		8
Registered Direct Offering 2018 [Member] | Class Of Series G Warrant [Member]
Percentage of Warrants Per Unit		75
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.70
Registered Direct Offering 2019 [Member]
Stock Issued During Period, Shares, New Issues (in shares)	8,615,384
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 0.325
Number Of Accredited Investors	5
Registered Direct Offering 2019 [Member] | Class Of Series H Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.40

Note 7 - Derivative Liabiliti_5

Note 7 - Derivative Liabilities (Details Textual) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Derivative Liability, Total	$ 1,628,113
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total	108,944	$ 679,271
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member]
Cash Price Per Each Common Stock Underlying Warrants	0.18
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member]
Cash Price Per Each Common Stock Underlying Warrants	0.11
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member]
Cash Price Per Each Common Stock Underlying Warrants	$ 0.0533

Note 7 - Derivative Liabiliti_6

Note 7 - Derivative Liabilities - Fair Value Measurements (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member]
Beginning balance at September 30, 2020	$ 1,000,000	$ 1,000,000
Adjustments to estimated fair value	0	0
Ending balance at September 30, 2021	1,000,000	1,000,000
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member]
Beginning balance at September 30, 2020	748,275	748,275
Adjustments to estimated fair value		0
Ending balance at September 30, 2021	748,275	748,275
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member]
Beginning balance at September 30, 2020	568,144	1,247,415
Adjustments to estimated fair value	(108,944)	(679,271)
Ending balance at September 30, 2021	$ 459,200	$ 568,144

Note 7 - Derivative Liabiliti_7

Note 7 - Derivative Liabilities - Derivative Liabilities (Details)	12 Months Ended
	Sep. 30, 2021 $ / shares	Sep. 30, 2020 $ / shares	Jun. 30, 2022 $ / shares
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member]
Common Stock, Par Value (in dollars per share)	$ 0.12	$ 0.17
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Exercise Price [Member]
Measurement Input	0.75	0.75
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Price Volatility [Member]
Measurement Input	90.28	84.17
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input	0.04	0.13
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Expected Term [Member]
Remaining expected term of underlying securities (years) (Year)	4 months 2 days	1 year 4 months 6 days
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member]
Common Stock, Par Value (in dollars per share)	$ 0.12	$ 0.17
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Exercise Price [Member]
Measurement Input	0.7	0.7
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Price Volatility [Member]
Measurement Input	87.4	83.31
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input	0.19	0.15
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Expected Term [Member]
Remaining expected term of underlying securities (years) (Year)	1 year 8 months 12 days	2 years 8 months 15 days
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member]
Common Stock, Par Value (in dollars per share)	$ 0.12	$ 0.17
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Exercise Price [Member]
Measurement Input	0.4	0.4
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Price Volatility [Member]
Measurement Input	86.59	82.24
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input	0.41	0.22
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Expected Term [Member]
Remaining expected term of underlying securities (years) (Year)	2 years 6 months 29 days	3 years 7 months 6 days

Note 8 - October 2019 Registe_3

Note 8 - October 2019 Registered Direct Offering (Details Textual)				12 Months Ended
	Oct. 18, 2019 USD ($) $ / shares shares	Oct. 16, 2019 $ / shares shares	Oct. 10, 2019 USD ($)	Sep. 30, 2021 shares
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				1,071,429
Class of Series I Warrant [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares				0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				14,285,714
Proceeds from Subscribed, Unissued Common Stock and Warrants | $			$ 2,500,000
Payments of Stock Issuance Costs | $			$ 158,000
Class of Series I Warrant [Member] | Minimum [Member]
Percentage of Fee on Gross Proceeds of Warrants	6
Class of Series I Warrant [Member] | Maximum [Member]
Percentage of Fee on Gross Proceeds of Warrants	8.2
Registered Direct Offering October 2019 [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	14,285,714	14,285,714
Shares Issued, Price Per Share (in dollars per share) | $ / shares		$ 0.175
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.22
Proceeds from Subscribed, Unissued Common Stock and Warrants | $	$ 2,500,000
Payments of Financing Costs, Total | $	333,000
Payments of Stock Issuance Costs | $	$ 158,000
Registered Direct Offering October 2019 [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.21875
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	1,071,429
Warrants and Rights Outstanding, Term (Year)	5 years

Note 9 - 2021 Registered Dire_3

Note 9 - 2021 Registered Direct Offering (Details Textual)				12 Months Ended
	Feb. 17, 2021 shares	Feb. 11, 2021 USD ($) $ / shares shares	Feb. 08, 2021	Sep. 30, 2021 $ / shares shares	Jun. 30, 2022 $ / shares shares	Jun. 30, 2021 shares	Sep. 30, 2020 $ / shares
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 0.001	$ 0.001		$ 0.001
Series K Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		32,343,754			32,343,754
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.17
Warrants and Rights Outstanding, Term (Year)		5 years 6 months
Placement Agent 2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		3,234,375			3,234,375
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.20
Registered Direct Offering 2021 [Member]
Stock Issued During Period, Shares, New Issues (in shares)	43,125,004	43,125,004
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares		$ 0.001
Shares Issued, Price Per Share (in dollars per share) | $ / shares		$ 0.16
Payments of Stock Issuance Costs | $		$ 700,000
Percentage Of Fee On Gross Proceeds From Investors Participating in 2021 Financing			7.5
Percentage Of Fee On Gross Proceeds From Investors Participating with Pre-existing Relationships		6
One-Time Non-Accountable Expense Fee | $		$ 10,000
Maximum Fees And Expenses Of Legal Counsel And Other Out-Of-Pocket Expenses | $		50,000
Clearing Expenses | $		$ 10,000
Placement Agent's Fees, Percent of Warrants to Purchase Aggregate Number of Shares Sold		7.5
Registered Direct Offering 2021 [Member] | Series K Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		32,343,754
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.17
Warrants and Rights Outstanding, Term (Year)		5 years 6 months
Proceeds from Issuance or Sale of Equity, Total | $		$ 6.9
Class of Warrant or Right, Outstanding (in shares)						32,343,754
Registered Direct Offering 2021 [Member] | Placement Agent 2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		3,234,375
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.20
Class of Warrant or Right, Exercised (in shares)				0
Class of Warrant or Right, Outstanding (in shares)						3,234,375

Note 10 - Convertible Notes (De

Note 10 - Convertible Notes (Details Textual)					1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 06, 2020 USD ($) $ / shares shares	Jun. 22, 2020 USD ($) $ / shares shares	Jun. 04, 2020 USD ($) $ / shares shares	Jun. 03, 2020 USD ($)	Jun. 30, 2020 shares	Jun. 30, 2022 USD ($) $ / shares	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) $ / shares	Jun. 30, 2021 USD ($)	Sep. 30, 2021 USD ($) $ / shares	Sep. 30, 2020 USD ($) $ / shares
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares						$ 0.001		$ 0.001		$ 0.001	$ 0.001
Proceeds from Warrant Exercises | $										$ 0	$ 932,728
Interest Expense, Total | $						$ 39,890	$ 40,186	$ 119,671	$ 110,202	150,531	18,534
Series D Warrants [Member] | The 2015 Private Placement [Member]
Proceeds from Warrant Exercises | $		$ 82,000		$ 850,000
Common Stock Issuance Upon Exercise Of Warrants (in shares) | shares		454,546			4,727,273
Series J Warrants [Member] | The 2015 Private Placement [Member]
Common Stock Issuance Upon Exercise Of Warrants (in shares) | shares	3,375,000	340,910	3,545,454
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.25	$ 0.25
Warrants and Rights Outstanding, Term (Year)	30 years	1 year	1 year
Convertible Notes Payable Series One [Member]
Debt Instrument, Face Amount | $	$ 1,050,000		$ 550,000
Debt Instrument, Term (Year)	3 years
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 0.25		$ 0.27
Convertible Notes Payable [Member]
Debt Conversion, Original Debt, Interest Rate of Debt	10%
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.001
Debt Instrument, Convertible, Minimum Volume Weighted Average Price Trigger (in dollars per share) | $ / shares	$ 0.32
Number of Consecutive Trading Days for Minimum Volume Weighted Average Price Trigger (Year)	15 years
Percentage on Unpaid Principal Amount for Outstanding Note Obligations	35
Percentage on Interest for Outstanding Note Obligations	10
Interest Expense, Total | $										$ 150,000	$ 18,000

Note 11- Payroll Protection P_2

Note 11- Payroll Protection Program Loan (Details Textual) - USD ($)		12 Months Ended
	Apr. 25, 2020	Sep. 30, 2021	Sep. 30, 2020
Other Nonoperating Income (Loss) Debt Forgiveness Amount		$ 178,229	$ 0
Paycheck Protection Program Loan [Member]
Proceeds from Issuance of Debt	$ 176,300
Debt Instrument, Term (Year)	2 years
Debt Instrument, Interest Rate, Stated Percentage	1%
Debt Instrument, Periodic Payment, Total	$ 20,000
Other Nonoperating Income (Loss) Debt Forgiveness Amount		$ 178,000

Note 12 - Stock-based Compens_3

Note 12 - Stock-based Compensation (Details Textual) - USD ($)								3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 01, 2021	Sep. 27, 2021	Jul. 30, 2021	Jan. 27, 2021	Oct. 14, 2020	Jul. 19, 2018	Jun. 18, 2013	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Oct. 01, 2020
Common Stock, Shares Authorized (in shares)								800,000,000		800,000,000		800,000,000	800,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)										675,000		7,375,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum												79.44%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum												119.44%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum												0.13%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum												2.85%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate												0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)												5 years 7 months 6 days
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total								$ 230,633		$ 230,633
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)										1 year 9 months 14 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)												18,814,908
Restricted Stock [Member]
Share-Based Payment Arrangement, Expense								$ 10,000	$ 0	$ 30,000	$ 104,000
Non Employee Restricted Shares [Member]
Share-Based Payment Arrangement, Expense												$ 105,000	$ 220,000
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense												124,000	288,000
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense												$ 267,000	390,000
Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												24,479,212
Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												9,792,500
Employees Directors And Consultants [Member]
Share-Based Payment Arrangement, Expense												$ 391,000	$ 678,000
Employees [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)			150,000
The 2013 Plan [Member]
Common Stock, Shares Authorized (in shares)												31,114,256		34,114,256
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	3,000,000						3,000,000
Increase In Aggregate Number Of Shares (in shares)												3,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												0	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)								5,508,158		5,508,158		99,340
Share-Based Payment Arrangement, Expense								$ 81,000	94,000	$ 367,000	269,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total												$ 153,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)												2 years 5 months 19 days
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount												$ 43,000
The 2013 Plan [Member] | Restricted Stock [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)			50,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage						100%
The 2013 Plan [Member] | Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense								29,000	35,000	123,000	89,000
The 2013 Plan [Member] | General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense								$ 52,000	$ 59,000	$ 245,000	$ 180,000
The 2013 Plan [Member] | Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)										475,000		5,300,000
The 2013 Plan [Member] | Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)										200,000		2,075,000
The 2013 Plan [Member] | Consultants [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)		300,000		500,000	50,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					90 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Other (in shares)						220,000
The 2013 Plan [Member] | Consultants [Member] | Restricted Stock [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage		8.33%
The 2013 Plan [Member] | Board Of Directors And Management [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)						745,000

Note 12 - Stock-based Compens_4

Note 12 - Stock-based Compensation - Stock Compensation Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Outstanding (in shares)	24,899,014	18,248,346
Outstanding, weighted average exercise price (in dollars per share)	$ 0.29	$ 0.36
Outstanding, weighted average remaining contractual term (Year)	1 year 5 months 19 days	1 year 9 months 29 days	2 years 7 months 2 days
Outstanding, aggregate intrinsic value	$ 0	$ 140,151	$ 79,330
Awarded, shares (in shares)	675,000	7,375,000
Awarded, weighted average exercise price (in dollars per share)	$ 0.06	$ 0.12
Forfeited/Cancelled, shares (in shares)		(724,332)
Forfeited/Cancelled (in dollars per share)		$ 0.44
Outstanding (in shares)	22,490,196	24,899,014	18,248,346
Outstanding, weighted average exercise price (in dollars per share)	$ 0.28	$ 0.29	$ 0.36
Vested at September 30, 2021 (in shares)		18,814,908
Vested at September 30, 2021 (in dollars per share)		$ 0.35
Vested at September 30, 2021 (Year)		2 years 2 months 1 day
Vested at September 30, 2021		$ 17,122
Vested and expected to vest (in shares)	22,490,196	24,899,014
Vested and expected to vest at September 30, 2021 (in dollars per share)		$ 0.29
Vested and expected to vest at September 30, 2021 (Year)		1 year 9 months 29 days
Vested and expected to vest at September 30, 2021		$ 140,151

Note 12 - Stock-based Compens_5

Note 12 - Stock-based Compensation - Restricted Stock Activity (Details) - shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Non Vested (in shares)	0
Non Vested (in shares)	450,000	0
The 2013 Plan [Member]
Non Vested (in shares)	0	965,000
Awarded (in shares)	1,000,000	0
Vested (in shares)	(550,000)	(965,000)
Forfeited (in shares)	0	0
Non Vested (in shares)		0

Note 12 - Stock-based Compens_6

Note 12 - Stock-based Compensation - Restricted Stock Weighted Average Grant Date Fair Value (Details) - $ / shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Non Vested (in dollars per share)	$ 0	$ 0.43
Awarded (in dollars per share)	0.13	0
Vested (in dollars per share)	(0.16)	(0.43)
Forfeited (in dollars per share)	0	0
Non Vested (in dollars per share)	$ 0.10	$ 0

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Sep. 30, 2021	Mar. 31, 2022	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Lessee, Operating Lease, Term of Contract (Year)	3 years
Accrued Rent	$ 42,000	$ 21,000	$ 42,000	$ 39,600	$ 38,400
Operating Lease, Right-of-Use Asset	0		39,000
Operating Lease, Liability, Total	$ 0		$ 39,000
Patents [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years
M I T Licensing Agreement [Member]
Contractual Obligation, Total	$ 50,000

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Description of Business (Details Textual) - $ / shares	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001	$ 0.001

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Cash Equivalents, at Carrying Value, Total	$ 0		$ 0		$ 0	$ 0
Asset Impairment Charges, Total	$ 0	$ 0	$ 0	$ 0

Note 3 - Property and Equipme_7

Note 3 - Property and Equipment (10Q) (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Depreciation, Total	$ 799	$ 799	$ 2,397	$ 1,788	$ 2,587	$ 6,926

Note 3 - Property and Equipme_8

Note 3 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Property and equipment, gross	$ 33,756	$ 33,756	$ 30,481
Less – accumulated depreciation	(30,913)	(28,516)	(25,929)
Property and equipment, net	$ 2,843	$ 5,240	4,552
Furniture and Fixtures [Member]
Estimated useful life (Year)	5 years	5 years
Property and equipment, gross	$ 9,357	$ 9,357	9,357
Leasehold Improvements [Member]
Property and equipment, gross	$ 8,983	$ 8,983	8,983
Computer Equipment [Member]
Estimated useful life (Year)	3 years	3 years
Property and equipment, gross	$ 14,416	$ 14,416	$ 11,141
Equipment [Member]
Estimated useful life (Year)	5 years
Property and equipment, gross	$ 1,000	$ 1,000

Note 4 - Inventories - Inventor

Note 4 - Inventories - Inventories (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Finished goods	$ 0	$ 249,571
Goods-in-process	1,428,264	844,194
Total	$ 1,428,264	$ 1,093,765	$ 967,993

Note 5 - Stock-based Compensa_3

Note 5 - Stock-based Compensation (Details Textual) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 01, 2021	Jun. 18, 2013	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					675,000		7,375,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)					0	0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 230,633		$ 230,633
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					1 year 9 months 14 days
Restricted Stock [Member]
Share-Based Payment Arrangement, Expense			$ 10,000	$ 0	$ 30,000	$ 104,000
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense							$ 124,000	$ 288,000
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense							$ 267,000	$ 390,000
Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)							24,479,212
Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)							9,792,500
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	34,114,256	31,114,256
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	3,000,000	3,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)							0	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)			5,508,158		5,508,158		99,340
Share-Based Payment Arrangement, Expense			$ 81,000	94,000	$ 367,000	269,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total							$ 153,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)							2 years 5 months 19 days
The 2013 Plan [Member] | Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense			29,000	35,000	123,000	89,000
The 2013 Plan [Member] | General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense			$ 52,000	$ 59,000	$ 245,000	$ 180,000
The 2013 Plan [Member] | Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					475,000		5,300,000
The 2013 Plan [Member] | Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					200,000		2,075,000

Note 5 - Stock-based Compensa_4

Note 5 - Stock-based Compensation - Stock Compensation Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Outstanding (in shares)	24,899,014	18,248,346
Outstanding, weighted average exercise price (in dollars per share)	$ 0.29	$ 0.36
Outstanding, weighted average remaining contractual term (Year)	1 year 5 months 19 days	1 year 9 months 29 days	2 years 7 months 2 days
Outstanding, aggregate intrinsic value	$ 0	$ 140,151	$ 79,330
Awarded (in shares)	675,000	7,375,000
Awarded, weighted average exercise price (in dollars per share)	$ 0.06	$ 0.12
Forfeited/Cancelled (in shares)	(3,083,818)
Forfeited/Cancelled, weighted average exercise price (in dollars per share)	$ 0.33
Outstanding (in shares)	22,490,196	24,899,014	18,248,346
Outstanding, weighted average exercise price (in dollars per share)	$ 0.28	$ 0.29	$ 0.36
Vested (in shares)	19,135,976
Vested, weighted average exercise price (in dollars per share)	$ 0.31
Vested, weighted average remaining contractual term (Year)	1 year 8 months 12 days
Vested and expected to vest (in shares)	22,490,196	24,899,014
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.28
Vested and expected to vest, weighted average remaining contractual term (Year)	1 year 5 months 19 days
Vested and expected to vest, aggregate intrinsic value	$ 0

Note 5 - Stock-based Compensa_5

Note 5 - Stock-based Compensation - Restricted Stock Activity (Details) - $ / shares	9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Non Vested (in shares)	450,000	0	0
Non Vested (in shares)			450,000	0
Non Vested (in dollars per share)	$ 0.10	$ 0	$ 0	$ 0.43
Awarded (in dollars per share)			0.13	0
Vested (in dollars per share)			(0.16)	(0.43)
Forfeited, weighted average fair value (in dollars per share)			0	0
Non Vested (in dollars per share)			$ 0.10	$ 0
Restricted Stock [Member]
Non Vested (in shares)	450,000	0	0
Awarded (in shares)	0	550,000
Vested (in shares)	(275,000)	(550,000)
Forfeited (in shares)	0	0
Non Vested (in shares)	175,000	0	450,000	0
Non Vested (in dollars per share)	$ 0.10	$ 0	$ 0
Awarded (in dollars per share)	0	0.19
Vested (in dollars per share)	(0.10)	(0.19)
Forfeited, weighted average fair value (in dollars per share)	0	0
Non Vested (in dollars per share)	$ 0.10	$ 0	$ 0.10	$ 0

Note 6 - Registered Direct Of_4

Note 6 - Registered Direct Offerings That Created Derivative Liabilities (Details Textual) - USD ($)				3 Months Ended			9 Months Ended
	May 12, 2019	Jun. 28, 2018	Feb. 20, 2017	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2016
Series F Warrant [Member]
Warrants and Rights, Percent of Stock Oustanding Callable			55%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.75
Class of Warrant or Right, Expired During Period (in shares)					5,591,664
Series G Warrant [Member]
Warrants and Rights, Percent of Stock Oustanding Callable		75%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.70
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				6,802,500			6,802,500
Series H Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				8,615,384			8,615,384
Series F, Series G, and Series H Warrants [Member]
Class of Warrant or Right, Warrants Exercised (in shares)				0		0	0	0
The 2017 SPA [Member]
Registered Direct Offering, Maximum Amount									$ 50,000,000
Stock Issued During Period, Shares, New Issues (in shares)			10,166,664
Shares Issued, Price Per Share (in dollars per share)			$ 0.60
The 2018 SPA [Member]
Stock Issued During Period, Shares, New Issues (in shares)		9,070,000
Shares Issued, Price Per Share (in dollars per share)		$ 0.50
The 2019 SPA [Member]
Stock Issued During Period, Shares, New Issues (in shares)	8,615,384
Shares Issued, Price Per Share (in dollars per share)	$ 0.325

Note 7 - Derivative Liabiliti_8

Note 7 - Derivative Liabilities (10Q) (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021
Derivative Liability, Total					$ 1,628,113
Derivative Warrant Liability [Member]
Derivative Liability, Total	$ 1,628,113		$ 1,628,113
Fair Value Adjustment of Derivatives	$ 0	$ 0	$ 0	$ 108,944
Series F Warrant [Member]
Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share)	$ 0.18		$ 0.18
Series G Warrant [Member]
Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share)	0.11		0.11
Series H Warrant [Member]
Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share)	$ 0.0533		$ 0.0533

Note 7 - Derivative Liabiliti_9

Note 7 - Derivative Liabilities - Fair Value of Derivative Liability (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Issuances	$ 0
Series F Warrant Derivative [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member]
Balance	1,000,000	$ 1,000,000
Issuances		0
Adjustments to estimated fair value	(1,000,000)	0
Balance	0	1,000,000
Series G Warrant Derivative [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member]
Balance	748,275	748,275
Issuances		0
Adjustments to estimated fair value	0	0
Balance	748,275	748,275
Series H Warrant Derivative [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member]
Balance	459,200	568,144
Issuances		0
Adjustments to estimated fair value	0	(108,944)
Balance	$ 459,200	$ 459,200

Note 7 - Derivative Liabilit_10

Note 7 - Derivative Liabilities - Derivative Liability Value Assumptions (Details) - Derivative Financial Instruments, Liabilities [Member]	Jun. 30, 2022	Sep. 30, 2021
Measurement Input, Share Price [Member] | Series G Warrant Derivative [Member]
Measurement Input	0.046	0.12
Measurement Input, Share Price [Member] | Series H Warrant Derivative [Member]
Measurement Input	0.046	0.12
Measurement Input, Share Price [Member] | Series F Warrant Derivative [Member]
Measurement Input		0.12
Measurement Input, Exercise Price [Member] | Series G Warrant Derivative [Member]
Measurement Input	0.70	0.70
Measurement Input, Exercise Price [Member] | Series H Warrant Derivative [Member]
Measurement Input	0.40	0.40
Measurement Input, Exercise Price [Member] | Series F Warrant Derivative [Member]
Measurement Input		0.75
Measurement Input, Price Volatility [Member] | Series G Warrant Derivative [Member]
Measurement Input	1.0618	0.8740
Measurement Input, Price Volatility [Member] | Series H Warrant Derivative [Member]
Measurement Input	0.9585	0.8659
Measurement Input, Price Volatility [Member] | Series F Warrant Derivative [Member]
Measurement Input		0.9028
Measurement Input, Risk Free Interest Rate [Member] | Series G Warrant Derivative [Member]
Measurement Input	0.0280	0.0019
Measurement Input, Risk Free Interest Rate [Member] | Series H Warrant Derivative [Member]
Measurement Input	0.0292	0.0041
Measurement Input, Risk Free Interest Rate [Member] | Series F Warrant Derivative [Member]
Measurement Input		0.0004
Measurement Input, Expected Dividend Rate [Member] | Series G Warrant Derivative [Member]
Measurement Input	0	0
Measurement Input, Expected Dividend Rate [Member] | Series H Warrant Derivative [Member]
Measurement Input	0	0
Measurement Input, Expected Dividend Rate [Member] | Series F Warrant Derivative [Member]
Measurement Input		0
Measurement Input, Expected Term [Member] | Series G Warrant Derivative [Member]
Measurement Input	0.94	1.70
Measurement Input, Expected Term [Member] | Series H Warrant Derivative [Member]
Measurement Input	1.83	2.58
Measurement Input, Expected Term [Member] | Series F Warrant Derivative [Member]
Measurement Input		0.34

Note 8 - October 2019 Registe_4

Note 8 - October 2019 Registered Direct Offering (Details Textual) - USD ($)		9 Months Ended
	Oct. 18, 2019	Jun. 30, 2022	Jun. 30, 2021
Series I Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.22
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		14,285,714
October 2019 Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.21875
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,071,429
Warrants and Rights Outstanding, Term (Year)	5 years
Series I and Placement Warrants [Member]
Class of Warrant or Right, Warrants Exercised (in shares)		0	0
Placement Fees [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1,071,429
October 2019 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	14,285,714
Shares Issued, Price Per Share (in dollars per share)	$ 0.175
Proceeds from Issuance or Sale of Equity, Total	$ 2,500,000
Payments of Stock Issuance Costs	$ 333,000
October 2019 Registered Direct Offering [Member] | Minimum [Member]
Securities Purchase Agreement, Cash Placement Fee	6%
October 2019 Registered Direct Offering [Member] | Maximum [Member]
Securities Purchase Agreement, Cash Placement Fee	8.20%
October 2019 Registered Direct Offering [Member] | Placement Fees [Member] | Wainwright [Member]
Payments of Stock Issuance Costs	$ 158,000

Note 9 - 2021 Registered Dire_4

Note 9 - 2021 Registered Direct Offering (Details Textual) - USD ($)		9 Months Ended
	Feb. 11, 2021	Jun. 30, 2022
Series K Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	32,343,754	32,343,754
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.17
Warrants and Rights Outstanding, Term (Year)	5 years 6 months
Placement Agent 2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	3,234,375	3,234,375
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.20
Warrants and Rights, Percent of Stock Oustanding Callable	7.50%
Series K and Placement Agent 2 Warrants [Member]
Class of Warrant or Right, Warrants Exercised (in shares)		0
The 2021 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	43,125,004
Shares Issued, Price Per Share (in dollars per share)	$ 0.16
Proceeds from Issuance or Sale of Equity, Total	$ 6,900,000
Payments of Stock Issuance Costs	700,000
The 2021 Registered Direct Offering [Member] | Non-accountable Expense Fee [Member]
Securities Purchase Agreement, Potential Fees	10,000
The 2021 Registered Direct Offering [Member] | Fees and Expenses of Legal Counsel and Other Out-of-pocket Expenses [Member]
Securities Purchase Agreement, Potential Fees	50,000
The 2021 Registered Direct Offering [Member] | Clearing Expenses [Member]
Securities Purchase Agreement, Potential Fees	$ 10,000
The 2021 Registered Direct Offering [Member] | Participating Investors [Member]
Securities Purchase Agreement, Cash Placement Fee	7.50%
The 2021 Registered Direct Offering [Member] | Certain Investors With Pre-existing Relationships [Member]
Securities Purchase Agreement, Cash Placement Fee	6%

Note 10 - Series 1 and Series_2

Note 10 - Series 1 and Series 2 Convertible Notes (Details Textual) - USD ($)				3 Months Ended	9 Months Ended		12 Months Ended
	Jun. 22, 2020	Jun. 04, 2020	Jun. 03, 2020	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Nov. 06, 2020
Proceeds from Warrant Exercises							$ 0	$ 932,728
Series D Warrants [Member]
Proceeds from Warrant Exercises	$ 82,000		$ 850,000
Class of Warrant or Right, Warrants Exercised (in shares)	454,546
Remaining Warrants [Member]
Class of Warrant or Right, Warrants Exercised (in shares)		4,727,273
Series J Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	340,910	3,545,454							3,375,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.25	$ 0.25
Warrants and Rights Outstanding, Term (Year)	1 year	1 year
Series 1 Convertible Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage		10%
Debt Instrument, Face Amount		$ 550,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.27
Series 1 Convertible Notes [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.32
Series 2 Convertible Notes [Member]
Debt Instrument, Face Amount									$ 1,050,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)									$ 0.25
Series 1 & 2 Convertible Notes [Member]
Interest Expense, Debt, Total				$ 40,000	$ 120,000	$ 110,000

Note 11 - Advances from Inves_2

Note 11 - Advances from Investors (Details Textual) - USD ($)	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Proceeds from Advances from Investors	$ 575,000	$ 0
President and Chief Executive Officer, Chief Financial Officer, and Board of Directors [Member]
Proceeds from Advances from Investors	$ 80,000

Note 12 - Payroll Protection _2

Note 12 - Payroll Protection Program Loan (Details Textual)	Apr. 25, 2020 USD ($)
Paycheck Protection Program Loan [Member]
Proceeds from Issuance of Debt	$ 176,300

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details Textual) - USD ($)		9 Months Ended
	Jul. 07, 2022	Jun. 30, 2022	Jun. 30, 2021	Nov. 06, 2020	Jun. 04, 2020
Proceeds from Advances from Investors		$ 575,000	$ 0
Series 1 Convertible Notes [Member]
Debt Instrument, Face Amount					$ 550,000
Debt Instrument, Interest Rate, Stated Percentage					10%
Series 2 Convertible Notes [Member]
Debt Instrument, Face Amount				$ 1,050,000
Subsequent Event [Member]
Percentage of Principal Amount	15%
Proceeds from Issuance of Convertible Notes, Common Stock and Warrants, Gross	$ 3,500,000
Proceeds from Advances from Investors	$ 600,000
Subsequent Event [Member] | Securities Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	12,766,600
Subsequent Event [Member] | Notes 2022 [Member]
Proceeds from Issuance of Private Placement	$ 2,400,000
Subsequent Event [Member] | Warrant Shares [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	85,110,664
Subsequent Event [Member] | Notes 2022 [Member]
Debt Instrument, Face Amount	$ 4,230,000
Debt Instrument, Unamortized Discount, Total	$ 710,000
Subsequent Event [Member] | Series 1 Convertible Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage	10%
Subsequent Event [Member] | Series 2 Convertible Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage	10%
Debt Instrument, Failure to Complete Uplist Transaction Fee, Percentage of Outstanding Principal	125%